EVENT NAVIGATION
PROGRAMME
08:30
Registration and Coffee in the Networking Surgery
09:30
Chair's Opening Address
Professor Carol V Robinson (confirmed)
Royal Society Research Professor of Biological Chemistry, Department of Chemistry, University of Cambridge
Professor Carol V Robinson (confirmed)
Royal Society Research Professor of Biological Chemistry, Department of Chemistry, University of Cambridge
09:35
Keynote Address
Sir Mark Walport (confirmed)
Director, The Wellcome Trust
“The Future Knowledge Economy.”
Discussing the relationship between biosciences and healthcare delivery. Given the global scientific challenges and turbulent economic climate what can be done to ensure the top scientific talent is successfully developed and nurtured? How can the UK science base increase growth and prosperity and how do we cover the cost of innovation? Discussing if science is equipped to deal with global pandemics such as swine flu.
View Presentation
Sir Mark Walport (confirmed)
Director, The Wellcome Trust
“The Future Knowledge Economy.”
Discussing the relationship between biosciences and healthcare delivery. Given the global scientific challenges and turbulent economic climate what can be done to ensure the top scientific talent is successfully developed and nurtured? How can the UK science base increase growth and prosperity and how do we cover the cost of innovation? Discussing if science is equipped to deal with global pandemics such as swine flu.
View Presentation
09:55
Dr Aileen Allsop (confirmed)
Joint-Chair, Science and Trust Expert Group; Vice President for Science Policy, Research and Design, AstraZeneca.
“The ethics of experimentation.”
Are moral responsibilities more important than advances in science and technology? Are innovative risks being too restricted by regulation? Should we seek to solve complex social problems through biological interventions?
View Presentation
Joint-Chair, Science and Trust Expert Group; Vice President for Science Policy, Research and Design, AstraZeneca.
“The ethics of experimentation.”
Are moral responsibilities more important than advances in science and technology? Are innovative risks being too restricted by regulation? Should we seek to solve complex social problems through biological interventions?
View Presentation
10:15
Gregory Stoloff (confirmed)
Chief Executive Officer, PepTcell
“Government Biotech Policy: Rhetoric or Commitment? ”
A Small Biotech Company's experience with respect to Pandemic Influenza
View Presentation
Chief Executive Officer, PepTcell
“Government Biotech Policy: Rhetoric or Commitment? ”
A Small Biotech Company's experience with respect to Pandemic Influenza
View Presentation
10:30-10:40
Question and Answer Session
10:45
Masterclass Session 1
A series of Masterclasses will run throughout the day. You have the opportunity to pick a stream from the following three topics: Healthcare & Business Development, Research and Development and Science to Wealth.
A series of Masterclasses will run throughout the day. You have the opportunity to pick a stream from the following three topics: Healthcare & Business Development, Research and Development and Science to Wealth.
11:30
Coffee in the Networking Surgery
12:15
Masterclass Session 2
13:00
Lunch in the Networking Surgery
14:00
Masterclass Session 3
14:45
Guest Speaker
Professor Clare Williams (confirmed)
Professor of Social Science of Biomedicine, Director Centre for Biomedicine & Society, King's College London
“Innovations in Biomedicine: The social context of ethics”
Where and how are ethical boundaries drawn in clinical and scientific practice? Who decides what choices are offered to patients? Is informed consent attainable?
View Presentation
Professor Clare Williams (confirmed)
Professor of Social Science of Biomedicine, Director Centre for Biomedicine & Society, King's College London
“Innovations in Biomedicine: The social context of ethics”
Where and how are ethical boundaries drawn in clinical and scientific practice? Who decides what choices are offered to patients? Is informed consent attainable?
View Presentation
15:00
Panel Debate
“Genomics and Stem Cell Research Developments & Debates.”
Will breakthroughs result in anything more than expensive treatments for affluent patients? Given the controversy that still surrounds embryonic stem cell research what can science do to overcome public mistrust? Will human genome sequencing be of benefit to health? With the US stem cell restrictions ending will this result in a brain drain of UK talent and investment opportunities?
“Genomics and Stem Cell Research Developments & Debates.”
Will breakthroughs result in anything more than expensive treatments for affluent patients? Given the controversy that still surrounds embryonic stem cell research what can science do to overcome public mistrust? Will human genome sequencing be of benefit to health? With the US stem cell restrictions ending will this result in a brain drain of UK talent and investment opportunities?
Chair Professor Clare Williams (confirmed)
Dr Sara Rankin (confirmed)
Reader in Leukocyte and Stem Cell Biology Imperial College; Editor of the British Journal of Pharmacology
Reader in Leukocyte and Stem Cell Biology Imperial College; Editor of the British Journal of Pharmacology
Dr Marcelo N. Rivolta (confirmed)
Senior Research Fellow, Centre for Stem Cell Biology, Department of Biomedical Science, The University of Sheffield
Senior Research Fellow, Centre for Stem Cell Biology, Department of Biomedical Science, The University of Sheffield
16:00
Chair's Closing Remarks
16:10
Coffee in the Networking Surgery
16:25
Conference Close